Triple
T36600429
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CLEOPATRA trial |
E902898
|
entity |
| Predicate | trastuzumabTarget |
P37016
|
FINISHED |
| Object | HER2 extracellular domain |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: HER2 extracellular domain | Statement: [CLEOPATRA trial, trastuzumabTarget, HER2 extracellular domain]
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: trastuzumabTarget Context triple: [CLEOPATRA trial, trastuzumabTarget, HER2 extracellular domain]
-
A.
hasMolecularTarget
chosen
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
-
B.
isTherapeuticTargetIn
Indicates that a biological entity (e.g., gene, protein, pathway) is used or proposed as a therapeutic target within a specified disease, condition, or treatment context.
-
C.
targetsReceptor
Indicates that one entity is directed toward, binds to, or is designed to act upon a specific receptor.
-
D.
hasTargetDisease
Indicates that an entity (such as a treatment, study, or intervention) is directed toward, intended to affect, or primarily concerned with a specified disease.
-
E.
isTumorAgnostic
Indicates that a treatment, biomarker, or effect applies across multiple tumor types regardless of the cancer’s tissue or organ of origin.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f76e66b7b88190848f7a3e1188915f |
completed | May 3, 2026, 3:48 p.m. |
| NER | Named-entity recognition | batch_69f7c371931c8190afb1d4dd5157f92c |
completed | May 3, 2026, 9:51 p.m. |
| PD | Predicate disambiguation | batch_69f7c1baf25c8190a78dd54a400d2c50 |
completed | May 3, 2026, 9:44 p.m. |
Created at: May 3, 2026, 4:11 p.m.